Biosimilar Red Tape Elimination Act
Latest Action
Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.
Official Summary
Biosimilar Red Tape Elimination Act This bill deems all biosimilars licensed by the Food and Drug Administration (FDA) interchangeable with their reference products. A biosimilar is a biological product (e.g., a drug or vaccine) that is very similar to a brand-name biological product (i.e., the reference product). Under current law, a biosimilar that meets additional requirements may be deemed interchangeable with the reference product; this designation allows pharmacists to substitute the interchangeable biosimilar when filling a prescription for the reference product, depending on state law. Further, the first biosimilar deemed interchangeable with a given reference product is awarded a period of marketing exclusivity. The bill eliminates additional requirements for demonstrating interchangeability so that all licensed biosimilars are deemed interchangeable with their reference products. (Draft guidance released by the FDA in 2024 proposed to make some of these interchangeability requirements optional, including studies related to the safety of switching between use of the biosimilar and reference product. It has not been finalized.) This change takes effect 60 days after the bill is enacted, and previously licensed biosimilars must be deemed interchangeable with their reference products on that date. However, the bill preserves the exclusivity period for first interchangeable biosimilars licensed before the bill’s enactment. For example, if a new biosimilar licensed after the bill takes effect relies on the same reference product as an existing biosimilar that is subject to an unexpired exclusivity period, the new biosimilar is not deemed interchangeable with the reference product until the exclusivity period has ended.
GovScope Watchdog™
AI Government Intelligence™The Biosimilar Red Tape Elimination Act proposes to automatically designate all biosimilar products licensed by the FDA as interchangeable with their reference biological products. Currently, biosimilars must meet additional FDA requirements to gain this interchangeable status, which allows pharmacists to substitute them for the reference product under state laws. The bill removes these additional requirements, making all licensed biosimilars interchangeable 60 days after enactment. It preserves existing marketing exclusivity periods for biosimilars already deemed interchangeable before the bill’s enactment, delaying interchangeability for new biosimilars referencing products with unexpired exclusivity. This change aims to simplify the regulatory framework for biosimilars and potentially increase their use.
This bill eliminates extra FDA requirements for biosimilar interchangeability, automatically deeming all licensed biosimilars interchangeable with their reference products while maintaining existing exclusivity protections.
- All FDA-licensed biosimilars will be automatically considered interchangeable with their reference biological products 60 days after the bill’s enactment.
- The bill removes the current additional FDA requirements for demonstrating interchangeability, including studies on switching safety.
- Existing marketing exclusivity periods for first interchangeable biosimilars licensed before enactment are preserved, affecting when new biosimilars can be deemed interchangeable.
['Pharmaceutical manufacturers of biosimilars', 'Pharmacists and healthcare providers', 'Patients who may gain increased access to biosimilar treatments', 'The Food and Drug Administration (FDA) through simplified regulatory processes']
['Implementation challenges in updating state pharmacy substitution laws to align with the new federal automatic interchangeability designation.', 'Potential impacts on the incentives created by marketing exclusivity periods for biosimilar developers.', 'Oversight considerations regarding the safety and efficacy of biosimilars without the current additional interchangeability requirements.']
The bill is currently in process in the 119th Congress and was placed on the Senate Legislative Calendar under General Orders as of July 27, 2026. It addresses ongoing regulatory discussions about biosimilar interchangeability, following FDA draft guidance in 2024 that proposed making some interchangeability requirements optional but was not finalized. The bill reflects legislative efforts to streamline biosimilar approval and substitution processes.
High concern review — 3 hidden impact flags detected
GovScope reviewed 3 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['Increased use of biosimilars due to simplified interchangeability could lead to reduced healthcare costs for biological treatments.', 'Potential shifts in pharmaceutical market dynamics as exclusivity protections are preserved but interchangeability requirements are relaxed.', 'Possible need for states to revise pharmacy substitution laws to align with federal changes, affecting state legislative agendas.']
The bill’s removal of additional FDA interchangeability requirements reduces regulatory oversight that currently ensures safety in switching between biosimilars and reference products. Preservation of exclusivity periods maintains existing market protections but introduces complexity in timing for new biosimilars. Monitoring state law adaptations and the impact on substitution practices will be important for transparency and implementation oversight.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.